Literature DB >> 7734740

Are there any glycemic thresholds for the serious microvascular diabetic complications?

P Reichard1.   

Abstract

We randomized 102 patients with insulin-dependent diabetes to intensified treatment (n = 48 at baseline, n = 42 after 7.5 years) or standard treatment (n = 54 at baseline, n = 47 after 7.5 years). As has previously been reported, intensified treatment resulted in a retardation of retinopathy, nephropathy, and neuropathy. For the purpose of the present study, all patients were analyzed, and the complications related to the mean glycosylated hemoglobin (HbA1c) level. Patients with mild retinopathy at onset did not develop serious retinopathy, visual deterioration, or manifest nephropathy if their mean HbA1c during 7.5 years was below 7% (normal range, 3.9%-5.7%). Neuropathy only rarely developed in patients with HbA1c below 7%. Visual acuity in the patient group with more advanced retinopathy at baseline was also better preserved if the patient had lower HbA1c; also whereas these patients needed photocoagulation treatment just as often as the patients with higher HbA1c because of proliferative retinopathy or sight-threatening macular edema. The risk for the development of serious and disabling microvascular complications seems to be small in patients with insulin-dependent diabetes mellitus if they start intensified treatment when they have mild retinopathy, and achieve mean HbA1c levels below 7% (1.2 times the upper normal limit).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7734740     DOI: 10.1016/1056-8727(94)00008-c

Source DB:  PubMed          Journal:  J Diabetes Complications        ISSN: 1056-8727            Impact factor:   2.852


  6 in total

1.  Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).

Authors:  Rebecca Broe; Malin L Rasmussen; Ulrik Frydkjaer-Olsen; Birthe S Olsen; Henrik B Mortensen; Tunde Peto; Jakob Grauslund
Journal:  Diabetologia       Date:  2014-07-01       Impact factor: 10.122

2.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

3.  Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications.

Authors:  Zongzhong Tong; Zhenglin Yang; Shrena Patel; Haoyu Chen; Daniel Gibbs; Xian Yang; Vincent S Hau; Yuuki Kaminoh; Jennifer Harmon; Erik Pearson; Jeanette Buehler; Yuhong Chen; Baifeng Yu; Nicholas H Tinkham; Norman A Zabriskie; Jiexi Zeng; Ling Luo; Jennifer K Sun; Manvi Prakash; Rola N Hamam; Stephen Tonna; Ryan Constantine; Cecinio C Ronquillo; SriniVas Sadda; Robert L Avery; John M Brand; Nyall London; Alfred L Anduze; George L King; Paul S Bernstein; Scott Watkins; Lynn B Jorde; Dean Y Li; Lloyd Paul Aiello; Martin R Pollak; Kang Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-05       Impact factor: 11.205

4.  Effects of sulbutiamine on diabetic polyneuropathy: an open randomised controlled study in type 2 diabetics.

Authors:  K K Kiew; W B Wan Mohamad; A Ridzuan; M Mafauzy
Journal:  Malays J Med Sci       Date:  2002-01

5.  Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus: 10 years after the Diabetes Control and Complications Trial.

Authors:  Neil H White; Wanjie Sun; Patricia A Cleary; Ronald P Danis; Matthew D Davis; Dean P Hainsworth; Larry D Hubbard; John M Lachin; David M Nathan
Journal:  Arch Ophthalmol       Date:  2008-12

Review 6.  Targeting intensive versus conventional glycaemic control for type 1 diabetes mellitus: a systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.

Authors:  Pernille Kähler; Berit Grevstad; Thomas Almdal; Christian Gluud; Jørn Wetterslev; Søren Søgaard Lund; Allan Vaag; Bianca Hemmingsen
Journal:  BMJ Open       Date:  2014-08-19       Impact factor: 2.692

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.